Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.42 |
| ▸ | HTR6 | P50406 | 6/20 | 0.35 |
| ▸ | PER2 | O15055 | 2/20 | 0.32 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21027972 | 0.86 | PTGDR2 (0.45) | PTGDR2HTR6MEN1RAB9AKMT2A | |
| SCHEMBL21027857 | 0.81 | PTGDR2 (0.47) | PTGDR2HTR6PTGDR | |
| SCHEMBL21027976 | 0.81 | PTGDR2 (0.49) | PTGDR2PTGDR | |
| SCHEMBL21028324 | 0.77 | PTGDR2 (0.42) | PTGDR2PTGDR | |
| SCHEMBL21028025 | 0.74 | PTGDR2 (0.46) | PTGDR2PTGDR | |
| SCHEMBL21028005 | 0.72 | PTGDR2 (0.38) | PTGDR2HTR6PER2CRY1CRY2 | |
| SCHEMBL21028003 | 0.71 | PTGDR2 (0.49) | PTGDR2PTGDR | |
| SCHEMBL21027860 | 0.70 | PTGDR2 (0.49) | PTGDR2PTGDR | |
| SCHEMBL21028084 | 0.70 | PTGDR2 (0.50) | PTGDR2PTGDR | |
| SCHEMBL21028015 | 0.67 | ALDH1A1 (0.38) | PTGDR2MEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489235-A1 | TRICYCLIC COMPOUND AS CRTH2 INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-05-29 | — | — | EP | disclosed |